DOP23 Long-term health consequences of COVID-19 in patients with Inflammatory Bowel Diseases – A Danish prospective population-based cohort study

Autor: M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch

Publikováno v: Journal of Crohn's and Colitis. 16:i072-i074

Background The vast majority of patients with ulcerative colitis (UC) and Crohn’s disease (CD) who acquire coronavirus disease 2019 (COVID-19) survive the infection. Still, the long-term health consequences of COVID-19 are not well described in pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4e6cfd02b396dbbf5f6264d91c87adc6
https://doi.org/10.1093/ecco-jcc/jjab232.062

Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases - a Danish prospective population-based cohort study with individual-level data

Autor: Mohamed Attauabi, Klaus Theede, Lone Heimann Larsen, Tine Jess, Michael Dam Jensen, August Pilegaard Prahm, Asser Mathiassen Oppfeldt, Malte Rosager Hansen, Jakob Benedict Seidelin, Natalia Pedersen, Sule Eraslan, Marianne Kiszka-Kanowitz, Johan Burisch, Marianne Kajbæk Verner-Andersen, Anja Poulsen, Anders Berg Lødrup, Jens Frederik Dahlerup, Henning Glerup, Akbar Molazahi, Anders Neumann, Kent V. Haderslev

Publikováno v: Attauabi, M, Dahlerup, J F, Poulsen, A, Hansen, M R, Verner-Andersen, M K, Eraslan, S, Prahm, A P, Pedersen, N, Larsen, L, Jess, T, Neumann, A, Haderslev, K V, Molazahi, A, Lødrup, A B, Glerup, H, Oppfeldt, A M, Jensen, M D, Theede, K, Kiszka-Kanowitz, M, Seidelin, J B, Burisch, J & the Danish COVID-IBD Study Group 2022, ' Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases-a Danish prospective population-based cohort study with individual-level data ', Journal of Crohn's & colitis, vol. 16, no. 5, jjab192, pp. 757–767 . https://doi.org/10.1093/ecco-jcc/jjab192
Attauabi, M, Dahlerup, J F, Poulsen, A, Hansen, M R, Vester-Andersen, M K, Eraslan, S, Prahm, A P, Pedersen, N, Larsen, L, Jess, T, Neumann, A, Haderslev, K V, Molazahi, A, Lødrup, A B, Glerup, H, Oppfeldt, A M, Jensen, M D, Theede, K, Kiszka-Kanowitz, M, Seidelin, J B, Burisch, J & Danish COVID-IBD Study Group 2022, ' Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases-A Danish Prospective Population-Based Cohort Study with Individual-Level Data ', Journal of Crohn's & colitis, vol. 16, no. 5, pp. 757-767 . https://doi.org/10.1093/ecco-jcc/jjab192
Journal of Crohn's & Colitis

Background and Aims The health consequences of coronavirus disease 2019 [COVID-19] among patients with ulcerative colitis [UC] and Crohn’s disease [CD] remain largely unknown. We aimed to investigate the outcomes and long-term effects of COVID-19 i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65a5890016b3b0e98e6ebf85d3a910be
https://vbn.aau.dk/da/publications/085933f1-8b1a-4a20-bb1e-97f3a3710eb6

Long-term health consequences of COVID-19 in patients with Inflammatory Bowel Diseases - A Danish prospective population-based cohort study

Autor: Attauabi, M., Dahlerup, J. F., Poulsen, A., Hansen, M. R., Vester-Andersen, M. K., Eraslan, S., Prahm, A. P., Pedersen, N., Larsen, L., Jess, T., Neumann, A., Haderslev, K. V., Molazahi, A., Lødrup, A. B., Glerup, H., Oppfeldt, A. M., Jensen, M. D., Theede, K., Kiszka-Kanowitz, M., Seidelin, J. B., Burisch, J.

Publikováno v: Attauabi, M, Dahlerup, J F, Poulsen, A, Hansen, M R, Vester-Andersen, M K, Eraslan, S, Prahm, A P, Pedersen, N, Larsen, L, Jess, T, Neumann, A, Haderslev, K V, Molazahi, A, Lødrup, A B, Glerup, H, Oppfeldt, A M, Jensen, M D, Theede, K, Kiszka-Kanowitz, M, Seidelin, J B, Burisch, J & the Danish COVID-IBD Study Group 2022, ' Long-term health consequences of COVID-19 in patients with Inflammatory Bowel Diseases-A Danish prospective population-based cohort study ', Journal of Crohn's and Colitis, vol. 16, no. Suppl. 1, pp. I073-I076 . https://doi.org/10.1093/ecco-jcc/jjab232.062

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::57efe2cbcecbd2d0bab6df09058df920
https://vbn.aau.dk/da/publications/629ecd8d-ae47-43e1-a2bf-d9192f487d64

DOP22 Clinical, biochemical and endoscopic disease activity of Inflammatory Bowel Diseases are not associated with the severity or long-term outcomes of COVID-19 – A Danish prospective population-based cohort study

Autor: M Attauabi, J F Dahlerup, A Poulsen, M R Hansen, M K Vester-Andersen, S Eraslan, A P Prahm, N Pedersen, L Larsen, T Jess, A Neumann, K V Haderslev, A Molazahi, A B Lødrup, H Glerup, A M Oppfeldt, M D Jensen, K Theede, M Kiszka-Kanowitz, J B Seidelin, J Burisch

Publikováno v: Journal of Crohn's and Colitis. 16:i071-i072

Background Whether the disease activity of ulcerative colitis (UC) and Crohn’s disease (CD) is correlated with the severity of coronavirus disease 2019 (COVID-19) remains poorly investigated with only few selected cohort studies having addressed th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fb83cbaf015e18dbbb78a5f4dea237bc
https://doi.org/10.1093/ecco-jcc/jjab232.061

Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy - A real-world nationwide cohort of patients with inflammatory bowel diseases

Autor: Attauabi, M, Hoglund, C, Fassov, J, Pedersen, K B, Hansen, H Bansholm, Wildt, S, Jensen, M Dam, Neumann, A, Lind, C, Jacobsen, H Albaek, Popa, A M, Kjeldsen, J, Pedersen, N, Molazahi, A, Haderselv, K, Aalykke, C, Knudsen, T, Cebula, W, Munkholm, P, Bendtsen, F, Seidelin, J B, Johan, B

Publikováno v: Attauabi, M, Höglund, C, Fassov, J, Bo Pedersen, K, Hansen, H B, Wildt, S, Dam Jensen, M, Neumann, A, Lind, C, Jacobsen, H A, Popa, A M, Kjeldsen, J, Pedersen, N, Molazahi, A, Haderselv, K, Aalykke, C, Knudsen, T, Cebula, W, Munkholm, P, Bendtsen, F, Seidelin, J B & Johan, B 2021, ' Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy-A real-world nationwide cohort of patients with inflammatory bowel diseases ', Journal of Crohn's and Colitis, vol. 15, no. Suppl. 1, P347, pp. S369–S370 . https://doi.org/10.1093/ecco-jcc/jjab076.471
Attauabi, M, Hoglund, C, Fassov, J, Pedersen, K B, Hansen, H B, Wildt, S, Jensen, M D, Neumann, A, Lind, C, Jacobsen, H A, Popa, A M, Kjeldsen, J, Pedersen, N, Molazahi, A, Haderselv, K, Aalykke, C, Knudsen, T, Cebula, W, Munkholm, P, Bendtsen, F, Seidelin, J B & Johan, B 2021, ' Vedolizumab as first line biologic therapy in elderly patients with contraindications against anti-TNF therapy-A real-world nationwide cohort of patients with inflammatory bowel diseases ', Journal of Crohn's & colitis, vol. 15, no. Suppl. 1, pp. S369-S370 . https://doi.org/10.1093/ecco-jcc/jjab076.471

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c11e9ac186de1aa9d1bd72008019a413
https://portal.findresearcher.sdu.dk/da/publications/9f2725ba-6ae4-43ec-aa60-2f50f5f38ab1